pf-07220060
Small moleculeexperimental
Clinical trial activity
12 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
8
Phase 2
5
Phase 3
2
Phase 4
0
Earliest trial started Sep 23, 2020 (NCT04557449)
Timeline
Indications
Mechanism of action
- Cyclin-dependent kinase 4INHIBITOR
CDK4 inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07215078 | Phase 1 | Oct 8, 2025 | Pfizer |
| NCT07160738 | Phase 1 | Sep 22, 2025 | Pfizer |
| NCT07130097 | Phase 1 | Aug 14, 2025 | Pfizer |
| NCT06897683 | Phase 1 | Mar 21, 2025 | Pfizer |
| NCT06760637 | Phase 3 | Jan 6, 2025 | Pfizer |
| NCT06465368 | Phase 2 | Jul 11, 2024 | Pfizer |
| NCT06206837 | Phase 1/Phase 2 (Phase 2) | Feb 19, 2024 | Arvinas Inc, Pfizer |
| NCT06267963 | Phase 1 | Jan 31, 2024 | Pfizer |
| NCT06105632 | Phase 3 | Dec 15, 2023 | Pfizer |
| NCT05923411 | Phase 1 | Jul 11, 2023 | Pfizer |
| NCT05262400 | Phase 2 | Mar 14, 2022 | Pfizer |
| NCT04557449 | Phase 1 | Sep 23, 2020 | Pfizer |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 12 | 12 | 3 | 2020 |
| Arvinas Inc | For profit | 1 | 0 | 1 | 2024 |
2 organizations
Page 1 / 1